Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SSY Group ( (HK:2005) ) just unveiled an announcement.
SSY Group Limited reported unaudited turnover of approximately HK$1,227 million for the three months ended 31 March 2026, an 8.0% rise from a year earlier, driven notably by strong growth in bulk pharmaceuticals and certain IV and glass bottle solutions. However, gross profit slipped 1.3% to about HK$502 million, with gross margin narrowing by 3.8 percentage points to roughly 41.0%, reflecting product mix shifts and pressure on profitability.
Profit attributable to shareholders edged up 1.6% to around HK$171.2 million, suggesting modest earnings growth despite the margin compression in the period. Segment data showed a 61.2% surge in bulk pharmaceutical revenue and double-digit gains in upright soft bag and glass bottle IV solutions, offset by weaker performance in oral preparations, indicating a strategic tilt toward higher-volume bulk and infusion businesses that may reshape the Group’s earnings profile going forward.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates in the pharmaceutical sector with a focus on intravenous infusion solutions and related injectable products. Its portfolio spans non-PVC soft bag and other IV solutions, ampoule injections, bulk pharmaceuticals, oral preparations, medical materials, and ancillary products and services targeting hospital and medical markets.
YTD Price Performance: -18.73%
Average Trading Volume: 9,882,781
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.79B
Learn more about 2005 stock on TipRanks’ Stock Analysis page.